Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction.
Beta-blockers have been considered the cornerstone of treatment for patients with acute myocardial infarction (AMI). However, long-term benefits of vasodilating beta-blockers remain uncertain. This study aimed to investigate the long-term clinical benefits of vasodilating beta-blockers compared to c...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0326516 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850121268255260672 |
|---|---|
| author | Ki Yung Boo Miyeon Kim Jae-Geun Lee Geum Ko Joon Hyouk Choi Song-Yi Kim Seung-Jae Joo Jin-Yong Hwang Seung-Ho Hur Kwang Soo Cha Myung Ho Jeong KAMIR-NIH registry investigators |
| author_facet | Ki Yung Boo Miyeon Kim Jae-Geun Lee Geum Ko Joon Hyouk Choi Song-Yi Kim Seung-Jae Joo Jin-Yong Hwang Seung-Ho Hur Kwang Soo Cha Myung Ho Jeong KAMIR-NIH registry investigators |
| author_sort | Ki Yung Boo |
| collection | DOAJ |
| description | Beta-blockers have been considered the cornerstone of treatment for patients with acute myocardial infarction (AMI). However, long-term benefits of vasodilating beta-blockers remain uncertain. This study aimed to investigate the long-term clinical benefits of vasodilating beta-blockers compared to conventional beta-blockers in AMI patients with mildly reduced ejection fraction (mrEF). Among 13,624 patients who enrolled in the nationwide AMI database of South Korea, the KAMIR-NIH Registry, 2,662 AMI patients with mrEF, who were prescribed beta-blockers at discharge were selected for this study. The primary outcome was a composite of cardiac death, recurrent MI, or hospitalization for heart failure (HF) during 3-year follow up period. In the entire cohort, the use of vasodilating beta-blockers at discharge was associated with lower incidence of primary outcome at 3-year (hazard ratio [HR] 0.80; 95% confidence interval [CI], 0.62-0.98; P = 0.039) compared to the use of conventional beta-blockers at discharge. In the propensity score-matched (PSM) cohort, the use of vasodilating beta-blockers at discharge was also associated with a significantly lower incidence of primary outcome (HR, 0.66; 95% CI, 0.50-0.88; P = 0.004) compared to the use of conventional beta-blockers at discharge. Furthermore, in the PSM cohort, the use of vasodilating beta-blockers was associated with lower incidences of the cardiac death (HR, 0.60; 95% CI, 0.39-0.92; P = 0.020), hospitalization for HF (HR, 0.72; 95% CI, 0.46-0.98; P = 0.042), and all-cause death (HR, 0.67; 95% CI, 0.48-0.93; P = 0.017) compared to the use of conventional beta-blockers. However, no significant differences were observed between the groups in the incidences of recurrent MI (HR, 0.62; 95% CI, 0.34-1.14; P = 0.122), any revascularization (HR, 1.04; 95% CI, 0.76-1.42; P = 0.821), stroke (HR, 0.84; 95% CI, 0.44-1.60; P = 0.589), stent thrombosis (HR, 1.12; 95% CI, 0.40-3.11; P = 0.833). In AMI patients with mrEF, the use of vasodilating beta-blockers at discharge was associated with better long-term clinical outcomes compared to the use of conventional beta-blockers. |
| format | Article |
| id | doaj-art-d6e4ef252c784adcadc41cc2ae19d9dc |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-d6e4ef252c784adcadc41cc2ae19d9dc2025-08-20T02:35:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01206e032651610.1371/journal.pone.0326516Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction.Ki Yung BooMiyeon KimJae-Geun LeeGeum KoJoon Hyouk ChoiSong-Yi KimSeung-Jae JooJin-Yong HwangSeung-Ho HurKwang Soo ChaMyung Ho JeongKAMIR-NIH registry investigatorsBeta-blockers have been considered the cornerstone of treatment for patients with acute myocardial infarction (AMI). However, long-term benefits of vasodilating beta-blockers remain uncertain. This study aimed to investigate the long-term clinical benefits of vasodilating beta-blockers compared to conventional beta-blockers in AMI patients with mildly reduced ejection fraction (mrEF). Among 13,624 patients who enrolled in the nationwide AMI database of South Korea, the KAMIR-NIH Registry, 2,662 AMI patients with mrEF, who were prescribed beta-blockers at discharge were selected for this study. The primary outcome was a composite of cardiac death, recurrent MI, or hospitalization for heart failure (HF) during 3-year follow up period. In the entire cohort, the use of vasodilating beta-blockers at discharge was associated with lower incidence of primary outcome at 3-year (hazard ratio [HR] 0.80; 95% confidence interval [CI], 0.62-0.98; P = 0.039) compared to the use of conventional beta-blockers at discharge. In the propensity score-matched (PSM) cohort, the use of vasodilating beta-blockers at discharge was also associated with a significantly lower incidence of primary outcome (HR, 0.66; 95% CI, 0.50-0.88; P = 0.004) compared to the use of conventional beta-blockers at discharge. Furthermore, in the PSM cohort, the use of vasodilating beta-blockers was associated with lower incidences of the cardiac death (HR, 0.60; 95% CI, 0.39-0.92; P = 0.020), hospitalization for HF (HR, 0.72; 95% CI, 0.46-0.98; P = 0.042), and all-cause death (HR, 0.67; 95% CI, 0.48-0.93; P = 0.017) compared to the use of conventional beta-blockers. However, no significant differences were observed between the groups in the incidences of recurrent MI (HR, 0.62; 95% CI, 0.34-1.14; P = 0.122), any revascularization (HR, 1.04; 95% CI, 0.76-1.42; P = 0.821), stroke (HR, 0.84; 95% CI, 0.44-1.60; P = 0.589), stent thrombosis (HR, 1.12; 95% CI, 0.40-3.11; P = 0.833). In AMI patients with mrEF, the use of vasodilating beta-blockers at discharge was associated with better long-term clinical outcomes compared to the use of conventional beta-blockers.https://doi.org/10.1371/journal.pone.0326516 |
| spellingShingle | Ki Yung Boo Miyeon Kim Jae-Geun Lee Geum Ko Joon Hyouk Choi Song-Yi Kim Seung-Jae Joo Jin-Yong Hwang Seung-Ho Hur Kwang Soo Cha Myung Ho Jeong KAMIR-NIH registry investigators Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction. PLoS ONE |
| title | Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction. |
| title_full | Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction. |
| title_fullStr | Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction. |
| title_full_unstemmed | Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction. |
| title_short | Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction. |
| title_sort | long term benefit of vasodilating beta blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction |
| url | https://doi.org/10.1371/journal.pone.0326516 |
| work_keys_str_mv | AT kiyungboo longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT miyeonkim longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT jaegeunlee longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT geumko longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT joonhyoukchoi longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT songyikim longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT seungjaejoo longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT jinyonghwang longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT seunghohur longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT kwangsoocha longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT myunghojeong longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction AT kamirnihregistryinvestigators longtermbenefitofvasodilatingbetablockersinacutemyocardialinfarctionpatientswithmildlyreducedleftventricularejectionfraction |